Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen

Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia

(2015) Farhad Ravandi et al.   BRITISH JOURNAL OF HAEMATOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

(2014) Michael E. Rytting et al.   CANCER

Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia

(2014) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment of High-Risk Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial

(2014) Josep-Maria Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

Epilepsy: new genes, new technologies, new insights

(2013) Byung In Lee et al.   LANCET NEUROLOGY

The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia

(2013) Joshua Lukenbill et al.   Current Hematologic Malignancy Reports

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: Systematic review and meta-analysis

(2012) Ron Ram et al.   AMERICAN JOURNAL OF HEMATOLOGY

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

(2012) N. Gokbuget et al.   BLOOD

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Prospective Study on Incidence, Risk Factors, and Long-Term Outcome of Osteonecrosis in Pediatric Acute Lymphoblastic Leukemia

(2011) Mariël L. te Winkel et al.   JOURNAL OF CLINICAL ONCOLOGY

Polyethylene Glycol-conjugated L-asparaginase Versus Native L-asparaginase in Combination With Standard Agents for Children With Acute Lymphoblastic Leukemia in Second Bone Marrow Relapse

(2011) Joanne Kurtzberg et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

(2009) Giuseppe Basso et al.   JOURNAL OF CLINICAL ONCOLOGY

Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group

(2009) James B. Nachman et al.   JOURNAL OF CLINICAL ONCOLOGY

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Acute lymphoblastic leukemia in adolescents and young adults in Finland

(2008) A. Usvasalo et al.   HAEMATOLOGICA

Comparison of the Results of the Treatment of Adolescents and Young Adults With Standard-Risk Acute Lymphoblastic Leukemia With the Programa Español de Tratamiento en Hematología Pediatric-Based Protocol ALL-96

(2008) Josep-María Ribera et al.   JOURNAL OF CLINICAL ONCOLOGY

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

(2008) Ching-Hon Pui et al.   LANCET ONCOLOGY